Regarding the first approach we took advantage of the only two identified in the literature studies containing single cell data from melanoma patients following immunotherapy, particularly PD1, CTLA4 or combined inhibition and concurrently demonstrating the response status of these patients [43, 44] (Table S2). This evidence concerns the gene CTLA4 and melanoma.